Abstract：Objective To observe the effect of Apatinib combined with Gefitinib regimen in the treatment of patients with driver-gene positive advanced non-small cell lung cancer (NSCLC). Methods A total of 102 cases of driver-gene positive advanced NSCLC patients admitted to the Fifth People’s Hospital of Wuhu, Anhui Province were selected as the research objects from December 2017 to December 2019. They were divided into control group (51 cases) and study group (51 cases) according to the random number table method. The control group was given conventional treatment plan combined with Gefitinib, and the study group was given Apatinib treatment on the basis of the control group. The anti-tumor efficacy and the levels of tumor markers before and after treatment between two groups were compared; adverse reactions between two groups were observed; the two groups were followed up for 12 months to calculate the overall survival rate. Results Clinical control rate of study group was higher than that of control group, and the difference was statistically significant (P < 0.05); there was no significant difference in objective remission rate between two groups (P > 0.05). After treatment, the levels of carcinoembryonic antigen, CYFRA21-1, and carbohydrate antigen 125 in two groups were lower than those before treatment, and study group was lower than control group, and the differences were statistically significant (P < 0.05). The total incidence of hypertension and proteinuria in study group was higher than that of control group, and the difference was statistically significant (P < 0.05); there was no significant difference in the total incidence of bone marrow suppression and hand-foot syndrome between two groups (P > 0.05). The overall survival rate of study group was higher than that of control group, and the difference was statistically significant (P < 0.05). Conclusion Apatinib combined with Gefitinib regimen in the treatment of driver-gene positive advanced NSCLC can enhance the anti-tumor efficacy, reduce the content of tumor markers, prolong the short-term survival rate of patients and have good safety.
韩翠云 张士秀 洪秀. 阿帕替尼联合吉非替尼方案治疗驱动基因阳性晚期非小细胞肺癌患者的效果[J]. 中国医药导报, 2022, 19(17): 119-122.
HAN Cuiyun ZHANG Shixiu HONG Xiu. Effect of Apatinib combined with Gefitinib regimen in the treatment of patients with driver-gene positive advanced non-small cell lung cancer. 中国医药导报, 2022, 19(17): 119-122.
京公网安备 11010502046598号